Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a bullish outlook: Thirteen firms give Krystal Biotech a consensus “Moderate Buy” rating, with ten buys, one strong buy, and two holds. The average 12-month price target is $365.40, with recent targets ranging as high as $474.
• Krystal Biotech beat quarterly earnings expectations: The company reported $1.79 in earnings per share versus the $1.70 consensus estimate, while revenue reached $119.22 million. Analysts expect full-year earnings of approximately $7.48 per share.
• Insiders have recently sold shares: Insiders sold 51,000 shares worth $17.6 million over the past 90 days, although insiders still own 13.10% of the company. Institutional investors and hedge funds hold approximately 86.29% of the stock.

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $365.40.

Several analysts have weighed in on KRYS shares. HC Wainwright boosted their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a "buy" rating in a research note on Tuesday, June 16th. Jefferies Financial Group restated a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Weiss Ratings downgraded Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. Citigroup upped their target price on Krystal Biotech from $378.00 to $386.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Finally, Chardan Capital upgraded shares of Krystal Biotech to a "strong-buy" rating in a report on Monday, August 3rd.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company's stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company's stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 51,000 shares of company stock worth $17,558,270. Company insiders own 13.10% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Silvant Capital Management LLC acquired a new stake in Krystal Biotech in the second quarter valued at approximately $30,000. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech during the 1st quarter worth approximately $34,000. USA Financial Formulas acquired a new position in shares of Krystal Biotech during the 1st quarter worth approximately $44,000. Integrated Wealth Concepts LLC purchased a new position in shares of Krystal Biotech during the 2nd quarter valued at approximately $46,000. Finally, IFP Advisors Inc lifted its position in shares of Krystal Biotech by 248.7% during the 4th quarter. IFP Advisors Inc now owns 265 shares of the company's stock valued at $65,000 after buying an additional 189 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 0.6%

NASDAQ KRYS opened at $338.75 on Friday. Krystal Biotech has a 12-month low of $155.20 and a 12-month high of $382.54. The company has a fifty day simple moving average of $344.63 and a two-hundred day simple moving average of $312.11. The stock has a market cap of $10.03 billion, a P/E ratio of 42.45 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, sell-side analysts forecast that Krystal Biotech will post 7.48 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech's lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.